Cipla falls as its arm gets one observation for Goa facility
Cipla is currently trading at Rs. 1438.60, down by 7.30 points or 0.50% from its previous closing of Rs. 1445.90 on the BSE.
The scrip opened at Rs. 1447.50 and has touched a high and low of Rs. 1464.65 and Rs. 1435.45 respectively. So far 16396 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1702.00 on 09-Oct-2024 and a 52 week low of Rs. 1312.70 on 31-Jan-2024.
Last one week high and low of the scrip stood at Rs. 1464.65 and Rs. 1429.75 respectively. The current market cap of the company is Rs. 116340.84 crore.
The promoters holding in the company stood at 30.92%, while Institutions and Non-Institutions held 52.88% and 16.19% respectively.
United States Food and Drugs Administration (USFDA) has conducted an inspection at the manufacturing facility of Medispray Laboratories, wholly owned subsidiary of Cipla, located in Kundaim, Goa from January 14 - 20, 2025.
On conclusion of the inspection, Medispray received 1 observation in Form 483. The company will work closely with the USFDA and remains committed to address these observations comprehensively within stipulated time.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
